← TrialMatch
HomeTrials

PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study

The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, cours

Condition(s)PANS, PANDAS
StatusRecruiting
Study typeObservational
SummaryThe objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, course and outcome. The investigators aim to demonstrate they can recruit and retain 85% of children who are eligible for this study. Eligible children are those who fit criteria for PANS and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS). Each child will be followed for one year.
Who can participateInclusion Criteria (All participants): * Child age 3-17 years old * Child and their parent/guardian are able to complete all study activities in English * Potential participant's family plans to be followed within UW Health or Dartmouth Health for at least one year Inclusion Criteria (In primary care group only): * Pediatric patient who is a current member of the primary care population at either UW Health or Dartmouth Health * Abrupt onset of symptoms (within 7 days) occurring in the past 3 months. Willing to come in-person for at least the baseline visit. * Suspected diagnosis of PANS or PANDAS based on published criteria: * PANS: (A) Abrupt, dramatic, overnight onset of obsessive compulsive disorder (OCD) or severely restricted food intake; (B) concurrent abrupt onset of additional seve
Ages3 Years to 17 Years
SexAll
Lead sponsorUniversity of Wisconsin, Madison
LocationsLebanon, New Hampshire, United States; Madison, Wisconsin, United States
Start date2025-02-17
NCT IDNCT06811935
Official listinghttps://clinicaltrials.gov/study/NCT06811935

🔍 Search all trials →